| abstract |
This invention relates, e.g., to a method for identifying a class of subjects having MLL who are likely to be responsive to treatment with an inhibitor of a member of the AMPK signaling pathway. The method comprises measuring the amount of phosphorylation at particular residues of members of the AMPK signal transduction pathway, e.g. residues S428 of LKB l, S485 of AMPKα, S108 of AMPKβ, and/or Sl 16 of eNOS III, in a sample from the subject, wherein a significantly elevated level of phosphorylation at one or more of the residues compared to a baseline value indicates that the subject is likely to be responsive to treatment with an inhibitor of a member of the AMPK signaling pathway. In one embodiment of the invention, a subject which is determined to be likely to responsive to treatment with an inhibitor of a member of the AMPK signaling pathway, by a method as above, is administered an effective amount of an inhibitor of production or activity of one or more of the phosphoproteins of the signaling pathway. |